[Kidney transplant failure and retransplantation.]. / Fallimento di trapianto renale, rientro in dialisi e retrapianto.

Transplant failure is a more and more frequent cause of end stage renal failure and dialysis. Patient survival rate after graft failure is very varied according to different reports. Better survival is mainly a consequence of good continuum of care thanks to improved interaction between dialysis and transplant center. Diabetic and elderly patients, as well as patients affected by cardiovascular disease are the subjects at higher risk: if judged clinically adequate to enter the waiting list, they should be retransplanted as soon as possible. Dialysis survival of patients with failed kidney transplant is strictly linked to adequate dialysis dose. Second transplant survival rate is higher in the case of a living donor and if the first transplant survived longer. Good immunologic match is also a condition linked to higher graft and patient survival rate. High body mass index, smoking and severe cardiovascular comorbidity should be avoided. Whether to keep low immunosuppression levels after first graft failure and whether to excise the failed kidney, even though it shows no clinical problems, are issues still under debate. Low-dose immunosuppression is not recommended since it may result in higher rate of infectious and neoplastic diseases. The failed kidney should be removed not only in the case of clinical disease, but also when the retained failed kidney is associated with chronic inflammation, as shown by high C-reactive protein levels and erythropoietin resistance.

Chronic kidney disease is still present after renal transplantation with excellent function.

According to a k/DOQI work group, chronic kidney disease (CKD) can be present also in subjects with glomerular filtration rate (GFR) >90 mL/min or a serum creatinine (sCr) below 1.3 mg/dL. The aim of this study was to document the prevalence of clinical or biologic abnormalities among 190 cadaveric renal transplant patients with excellent and stable renal function at 6 months after transplantation as well as 5 years later. The recipients were 82 women and 108 men of mean age at transplantation of 44.56 +/- 11.73 years. All patients were on Neoral-based immunosuppression with at least 5-year follow-up. Mean sCr was 1.18 +/- 0.2 mg/dL. Mean GFR was 78.57 +/- 27.06 mL/min. Systolic blood pressure was >130 mm Hg in 56.6%, although 78.3% of patients were on antihypertensive therapy; 34.3% were anemic; 75.4% had serum cholesterol >200 mg/dL; 62.2% had serum triglyceride levels >170 mg/dL. Serum intact parathyroid hormone >100 pg/mL was observed in 38% of patients and 43% were on vitamin D supplementation, and 11.4% had developed posttransplant diabetes mellitus. With respect to controls, von Willebrand factor was higher in 81.2% (P < .0001; RR = 11); serum homocysteine levels in 75% (P < 0.001; RR = 7.61); PAI-1 in 37.5% (P = .0009; RR = 4). At 5 years posttransplantation we observed an overall improvement in these abnormalities. The vast majority of renal transplant patients with excellent graft function belong to stage 1 of CKD being affected by hypertension, dyslipidemia, anemia, and residual hyperparathyroidism. Markers of endothelial dysfunction were largely abnormal, a condition that could predispose to cardiovascular events.